Kenneth P Thompson

US Patent:

6086608, Jul 11, 2000

Filed:

Jan 14, 1997

Appl. No.:

8/783126

Inventors:

Steven W. Ek - Bolton MA
Kenneth K. Thompson - Palm Harbor FL
Randall D. Ross - Largo FL
Jose Lizardi - Franklin MA

Assignee:

Smith & Nephew, Inc. - Andover MA

International Classification:

A61B 1704

US Classification:

606232

Abstract:

A suture securing device includes an outer member with a suture receiving passage and an inner member configured for progressive insertion within the suture receiving passage and engagement with the outer member in any one of a plurality of locked positions to secure a suture between the inner member and the outer member. The suture receiving passage includes a threaded portion and the inner member includes a ridge for progressive engagement with threads of the threaded portion. A suture securing cartridge includes a sleeve having an axial bore with the outer member disposed in the bore at a distal end of the sleeve, the inner member disposed in the bore proximally of the outer member, and a carrier which engages the inner member to align the inner member with the suture receiving passage.

US Patent:

46275487, Dec 9, 1986

Filed:

Apr 26, 1985

Appl. No.:

6/727677

Inventors:

Kenneth H. Thompson - Kensington MD

International Classification:

B65D 4104

US Classification:

215295

Abstract:

Injury to a user's hand when removing a serrated twist-of cap from a container is prevented by a continuous band of gripping material circumscribing the serrations. The band may be a plastic material sprayed or painted onto the cap in liquid form and allowed to dry and adhere to the serrations. Alternatively, the band may be heat-shrunk about the cap periphery. In another embodiment, the band is a resilient plastic cover secured to the cap in a snap-fit engagement by means of an inwardly projecting annular lip arranged to snap over and engage the lower edge of the serrated cap. In the latter embodiment, the cover is provided with projections or ridges positioned and sized to engage corresponding recesses in the serrated cap sidewall. The band is made of a material which will not slip in the user's hand when the band and cap are twisted/turned.

US Patent:

44387270, Mar 27, 1984

Filed:

Jan 22, 1982

Appl. No.:

6/341794

Inventors:

Kenneth H. Thompson - Kensington MD

International Classification:

A01K 2900

US Classification:

119 29

Abstract:

A mobile unit for a kitten or similar animal includes at least two freely suspended rods, one of which is suspended from the other, with unequal torques applied about their off-center suspension points so that both rods, at rest, are skewed relative to horizontal. Pulling, tugging or otherwise disturbing a toy-like member, suspended from the lower rod, causes both rods to dip and bob irregularly in addition to rotating. This compound irregular motion, in both horizontal and vertical planes, is translated to the toy-like member with the result that the cat or other animal is attracted thereto. The mobile unit may be suspended from a door-way and the applied torques and suspension lengths may be made adjustable.

US Patent:

20210347899, Nov 11, 2021

Filed:

Sep 6, 2019

Appl. No.:

17/285793

Inventors:

- Newton MA, US
Kenneth Evan THOMPSON - Arlington MA, US

International Classification:

C07K 16/28

Abstract:

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes including treatment of cancers and to increase the effectiveness of vaccines.

US Patent:

20190292264, Sep 26, 2019

Filed:

Jun 2, 2017

Appl. No.:

16/306473

Inventors:

- Boston MA, US
Stefano Vincenzo Gulla - Medford MA, US
Kenneth Evan Thompson - Arlington VA, US

International Classification:

C07K 16/28
C12N 15/85
A61K 39/395
A61P 35/04

Abstract:

A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8 cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent. The methods can treat various cancers, for example melanoma, lung cancer, pancreatic cancer, glioma, breast cancer, and ovarian cancer.

US Patent:

20190194333, Jun 27, 2019

Filed:

Sep 15, 2017

Appl. No.:

16/327576

Inventors:

- Boston MA, US
Kenneth Evan Thompson - Arlington MA, US

International Classification:

C07K 16/28
A61P 37/08
A61P 37/06
A61P 35/00
A61K 47/68
C07K 14/705

Abstract:

A method of treating a subject can comprise administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1) depleting agent, thereby depleting CD8+ cytotoxic T and/or NK cells in vivo. A method of treating a subject can comprise administering to a subject in need thereof an effective amount of a KLRG1 depleting agent with effector killing function. A composition, for example an anti-KLRG1 antibody, can comprise a KLRG1 depleting agent. The methods and compositions can be used for various diseases in which KLRG1 is overexpressed, for example autoimmune diseases, transplant rejection, hematologic malignancies, and solid tumors.

US Patent:

20190085083, Mar 21, 2019

Filed:

Nov 28, 2018

Appl. No.:

16/203587

Inventors:

- Boston MA, US
Stefano Vincenzo Gulla - Boston MA, US
Kenneth Evan Thompson - Cambridge MA, US

International Classification:

C07K 16/28
A61P 35/04
A61P 35/00

Abstract:

A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent. The methods can treat various cancers, for example melanoma, lung cancer, pancreatic cancer, glioma, breast cancer, ovarian cancer, metastatic breast cancer, and colon cancer.